AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Analyze when to tilt toward stocks or bonds in retirement. A practical guide to selecting the right index mix for your goals.
22,201 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
When a board member sells 7,000 shares, traders and long-term investors want to know why. This article breaks down Fo...
European markets tumbled on Monday as new Middle East tensions joined the AI scare trade, pushing oil higher and risk...
The iShares MSCI Japan ETF is at the center of a major market overhaul in Japan, delivering broad exposure to a shift...
The social security cola forecast for 2027 climbs to 3.9%, driven by persistent inflation in housing and energy. Reti...
April data from the Mortgage Bankers Association show a modest uptick in mortgage payments, nudging homebuyer afforda...
Value stocks are delivering sharp gains in 2026 as earnings growth broadens beyond technology. Investors warn this fl...
After four days of tit-for-tat strikes, both sides signaled a pause in the Strait of Hormuz. Markets priced in a mana...
Memory prices are showing signs of life, and a small-cap memory company could ride the wave. This article explains wh...
Bitcoin prices retreat toward $60,000 while the Fear & Greed Index hits Extreme Fear. Here’s how traders assess risk,...
Leveraged Ether funds like ETHU are amplifying Ethereum moves even as crypto volatility spikes and regulators weigh a...
Carnival and Norwegian Cruise Line surged in midweek trading, signaling a partial rebound after a brutal month for cr...